Business Description
Vivos Inc
NAICS : 339112
SIC : 3845
ISIN : US92858K2042
Total Employee Number:
1Description
Vivos Inc is a radiation oncology medical device company engaged in the development of its yttrium-90 (Y-90) based precision radionuclide therapy devices. Its portfolio includes RadioGel Precision Radionuclide Therapy (Human Division) for treating solid tumors and positive surgical margins in humans and IsoPet (Animal Division) for treating solid tumors in animals. Vivos also sells PLGA-g-PEG polymers and PrecisionGel, a hydrogel polymer platform for delivering active pharmaceutical ingredients and therapeutic agents. The company currently mainly operates in the United States.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 23.17 | |||||
Equity-to-Asset | 0.91 | |||||
Debt-to-Equity | 0.04 | |||||
Debt-to-EBITDA | -0.04 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 24.72 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year FCF Growth Rate | -18.6 | |||||
3-Year Book Growth Rate | -7.2 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 33.48 | |||||
9-Day RSI | 38.53 | |||||
14-Day RSI | 40.16 | |||||
3-1 Month Momentum % | -22.12 | |||||
6-1 Month Momentum % | -0.29 | |||||
12-1 Month Momentum % | -41.43 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 15.11 | |||||
Quick Ratio | 14.78 | |||||
Cash Ratio | 14.69 | |||||
Days Inventory | 139.07 | |||||
Days Sales Outstanding | 53.35 | |||||
Days Payable | 314.38 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -7.9 | |||||
Shareholder Yield % | -5.26 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | -75.64 | |||||
Operating Margin % | -3650 | |||||
Net Margin % | -4380.77 | |||||
EBITDA Margin % | -3638.46 | |||||
FCF Margin % | -2800 | |||||
OCF Margin % | -2606.41 | |||||
ROE % | -137.73 | |||||
ROA % | -129.51 | |||||
ROIC % | -1330.37 | |||||
ROC (Joel Greenblatt) % | -1470.05 | |||||
ROCE % | -113.17 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 9.97 | |||||
Price-to-Tangible-Book | 9.97 | |||||
EV-to-EBIT | -9.53 | |||||
EV-to-EBITDA | -9.56 | |||||
EV-to-Revenue | 347.71 | |||||
EV-to-FCF | -12.42 | |||||
Earnings Yield (Greenblatt) % | -10.49 | |||||
FCF Yield % | -7.39 |
GF Valueâ„¢
Vivos Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Vivos Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-12 | In 138 days | ||
| Second quarter earnings results for 2026 | 2026-08-13 | In 47 days | ||
| General meeting for 2025 | 2026-07-01 | In 4 days | ||
| First quarter earnings results for 2026 | 2026-05-14 | 0.07 (+0.09%) | ||
| Annual report for 2025 | 2026-03-31 | 0.09 (+5.64%) | ||
| Third quarter earnings results for 2025 | 2025-11-12 | 0.09 (+1.55%) | ||
| Second quarter earnings results for 2025 | 2025-08-13 | 0.13 (+0.00%) | ||
| First quarter earnings results for 2025 | 2025-05-09 | 0.13 (-1.12%) | ||
| Annual report for 2024 | 2025-03-24 | 0.12 (-3.40%) | ||
| 0.125:1 Stock Split | 2019-06-28 | 0.03 (+26.67%) |
Show
Entries
Guru Commentaries on OTCPK:RDGL
No articles.
Articles on Vivos Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers